TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25432081
Drug: Placebo eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops instilled 4 times daily (n = 73)
Study: 21498494
Drug: Spinal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal morphine 100 µg + TAP block with bupivacaine 2 mg kg(‐1) (S(M)T(LA))
Study: 21498494
Drug: Spinal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal morphine 100 µg + TAP block with saline (S(M)T(S))
Study: 16421418
Drug: Dose-Intensive Epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-Intensive Epirubicin and Cyclophosphamide (DI-EC)
Study: 19468030
Drug: Standard-Dose Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose Chemotherapy (SD-CT)
Study: 16760197
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg Methylphenidate (MPH)
Study: 16760197
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg Atomoxetine (ATX)
Study: 24675657
Drug: N(G)-monomethyl-L-arginine
Normalized name: N(G)-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-monomethyl-L-arginine
Study: 31425478
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab treatment (0.5 mg in 0.05 ml via six intravitreal injections over 6 months)
Study: 21237502
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg, two tablets once daily)
Study: 18083770
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volume (V(T)) of 12 ml/kg without positive end-expiratory pressure (PEEP)
Study: 18083770
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (V(T)) of 6 ml/kg and 10 cmH(2)O PEEP
Study: 15454803
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin concentration, 70 g/L)
Study: 15454803
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin concentration, 100 g/L)
Study: 11688554
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Nonspi 5R = Np)
Study: 11688554
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (ViskenR = Vs)
Study: 11688554
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of pindolol
Study: 22106853
Drug: OROS MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OROS MPH 72 mg/day
Study: 22106853
Drug: OROS MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OROS MPH 54 mg/day
Study: 21501093
Drug: EpiCor(®) (EP)
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EpiCor(®) (EP) 500 mg
Study: 17874825
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg polaprezinc (zinc group)
Study: 11520252
Drug: Bivalent Hib-HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalent Hib-HB vaccine with DTP, OPV or IPV, DTaP, M-M-R(II)
Study: 3289583
Drug: Topical gentamicin
Normalized name: gentamicin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gentamicin solution
Study: 31394015
Drug: No traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No traditional medicines (n = 19)
Study: 26105600
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg once daily until progression/unacceptable toxicity)
Study: 26105600
Drug: Gemcitabine/cisplatin (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/cisplatin (GP) [G 1250 mg/m(2) i.v. days 1 and 8 (3-weekly cycle); P 75 mg/m(2) i.v. day 1, (3-weekly cycle) for up to four cycles]
Study: 1452917
Drug: Streptokinase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase treatment (anterior infarction)
Study: 1452917
Drug: Streptokinase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase treatment (inferior infarction)
Study: 2982266
Drug: Naloxone (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (1.4 mg/hr for 3 hours)
Study: 27236772
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg twice per day (b.i.d.) with dose titration
Study: 24140184
Drug: Placebo titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo titration
Study: 27236772
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg b.i.d. (nonrandomized patients)
Study: 22466511
Drug: Endobronchial valves
Normalized name: AmproMed for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial valves treatment
Study: 7802571
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (1 g of cephalothin sodium intravenously 30 minutes before the procedure and 500 mg of cephalexin orally every 6 hours for 3 days after the procedure)
Study: 353833
Drug: L-tryptophan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (2 g) + oxprenolol (80 mg)
Study: 31172867
Drug: Tablet computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer monitoring of upper limb exercise program
Study: 31331372
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy (HFNT) set at 37°C and 60 L/min
Study: 31331372
Drug: Noninvasive ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive ventilation (NIV) applied through a mask with pressure support mode, PEEP set at 3-5 cmH2O, tidal volume between 6-8 ml/kg
Study: 22080588
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg b.i.d. for 12 weeks
Study: 21943027
Drug: Voclosporin (low-dose)
Normalized name: ethinyl estradiol
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voclosporin (low-dose)
Study: 21943027
Drug: Voclosporin (medium-dose)
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voclosporin (medium-dose)
Study: 21943027
Drug: Voclosporin (high-dose)
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voclosporin (high-dose)
Study: 12620524
Drug: High-fat, low-carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat, low-carbohydrate oral supplement (16.7% protein, 55.1% fat, 28.2% CHO)
Study: 9926766
Drug: Modified Widman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Widman flap and topical application of saturated citric acid at pH 1 for 3 minutes
Study: 11271288
Drug: High-sodium lactobionate/raffinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium lactobionate/raffinose solution
Study: 11271288
Drug: High-potassium lactobionate/raffinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potassium lactobionate/raffinose solution
Study: 2740166
Drug: Weekly home
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly home visiting
Study: 2740166
Drug: Monthly home
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly home visiting
Study: 8031165
Drug: 5‐FU administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU administration
Study: 377539
Drug: Intravenous gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gentamicin and clindamycin
Study: 24784698
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (200 μg, bid)
Study: 24784698
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (4 mg, bid)
Study: 15236888
Drug: Fusafungine plus
Normalized name: fusafungin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusafungine plus analgesic (acetaminophen)
Study: 15236888
Drug: Antibiotic (amoxicillin‐clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic (amoxicillin‐clavulanic acid) plus analgesic (acetaminophen)
Study: 11943263
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy + Tamoxifen
Study: 11943263
Drug: Control (never-users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (never-users of hormone replacement therapy)
Study: 8129156
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg and 8 mg (combined analysis)
Study: 8129156
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg (study 3)
Study: 2757151
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with adrenaline 1:200,000 (pH 3.9) 2 mg/kg
Study: 2757151
Drug: Alkalinised bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinised bupivacaine with adrenaline 1:200,000 (pH 6.4) 2 mg/kg
Study: 769506
Drug: Amantadine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 400 mg daily
Study: 769506
Drug: Amantadine 200
Normalized name: amantadine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 200 mg daily
Study: 769506
Drug: Amantadine 200
Normalized name: amantadine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 200 mg daily with pemoline 20 mg daily
Study: 22022584
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH) treatment
Study: 22022584
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (40 µg) PTH (1-34)
Study: 9576972
Drug: PTH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH treatment
Study: 16285323
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (previous treatment)
Study: 16285323
Drug: Elimination of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elimination of topical corticosteroids and gradual reduction of skin-care products
Study: 8179563
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 mcg/kg iv)
Study: 8179563
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg im)
Study: 3953214
Drug: 2 grams
Normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams of dicloxacillin as an intravenous infusion at the induction of anaesthesia
Study: 3953214
Drug: 2 grams
Normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams of dicloxacillin as an intravenous infusion 3 hours before surgery
Study: 3953214
Drug: 2 grams
Normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams of dicloxacillin as an intravenous infusion approximately 6 hours before surgery
Study: 29888581
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (2 Hz/100 Hz, 4‐8 mA) applied to specific acupuncture points, 3 times a week for 12 weeks
Study: 28622156
Drug: Isometric handgrip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isometric handgrip training five times weekly (two contractions of 2 min at 30% of maximal power with each arm)
Study: 28622156
Drug: Sham-handgrip training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-handgrip training five times weekly (two contractions of 2 min at 5% of maximal power with each arm)
Study: 25088860
Drug: Ultrasound-guided TAP
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided TAP block (30 mL of 0.25% bupivacaine with epinephrine)
Study: 25088860
Drug: Laparoscopic-guided TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic-guided TAP block (30 mL of 0.25% bupivacaine with epinephrine)
Study: 16416114
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy regimen (idarubicin, cytarabine, etoposide) (group A)
Study: 16416114
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy regimen (group A)
Study: 11094035
Drug: Spironolactone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (12.5 to 50 mg daily)
Study: 1798003
Drug: lacidipine (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: lacidipine (4-6 mg once a day)
Study: 7039160
Drug: mexiletine (MEX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: mexiletine (MEX; 400 mg)
Study: 7039160
Drug: mexiletine (MEX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: mexiletine (MEX; 600 mg)
Study: 7039160
Drug: mexiletine (MEX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: mexiletine (MEX; 800 mg)
Study: 7039160
Drug: lorcainide (LOR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorcainide (LOR; 200 mg)
Study: 7039160
Drug: lorcainide (LOR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorcainide (LOR; 300 mg)
Study: 7039160
Drug: lorcainide (LOR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorcainide (LOR; 400 mg)
Study: 31855716
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg) administered into the CPB pump prime
Study: 29247531
Drug: EMS add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMS add-on therapy
Study: 25288340
Drug: ropivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine + morphine + ketorolac
Study: 25288340
Drug: ropivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine + morphine + ketorolac + methylprednisolone
Study: 25288340
Drug: control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (saline solution, epinephrine, and cefazolin)
Study: 23925619
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy plus naltrexone (100 mg/d)
Study: 30516797
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy plus placebo
Study: 23925619
Drug: Supportive counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive counseling plus naltrexone (100 mg/d)
Study: 23925619
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg/d)
Study: 16484702
Drug: Cisplatin administration
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administration at dosages above 60 mg/m2
Study: 16484702
Drug: Cisplatin administration
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administration once every 2 weeks
Study: 16939913
Drug: Cisplatin administration
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administration
Study: 8102427
Drug: Azithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (single oral dose of 20 mg/kg)
Study: 8102427
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (6 weeks of topical tetracycline plus erythromycin for severe cases)
Study: 12566359
Drug: Paclitaxel low
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel low dose (1.28 microg/mm2)
Study: 12566359
Drug: Paclitaxel high
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel high dose (3.10 microg/mm2)
Study: 8824691
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (1.6 mg)
Study: 1457264
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol (4 mg)
Study: 1552354
Drug: Protein intakes
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intakes of 0.8 and 1.0 g.kg‐1.d‐1
Study: 1552354
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 0.6 g.kg‐1.d‐1
Study: 27334885
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.25% bupivacaine and methylprednisolone 16 mg per nerve
Study: 23841532
Drug: Tadalafil 2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 2.5-5 mg
Study: 18554657
Drug: Tubeless percutaneous
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubeless percutaneous nephrolithotomy (group 2 treatment)
Study: 10877459
Drug: Zanamivir 10
Normalized name: Zanamivir 10 mg/mL solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir 10 mg inhaled bd for 5 days
Study: 8596268
Drug: Haloperidol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (4 mg by mouth)
Study: 1370264
Drug: r‐metHuG‐CSF (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐metHuG‐CSF (3 to 10 micrograms/kg/day, daily subcutaneous injection for 4 months after 1 month of dose titration)
Study: 1370264
Drug: Observation for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation for 4 months followed by r‐metHuG‐CSF treatment
Study: 6476812
Drug: Rimantadine hydrochloride
Normalized name: Rimantadine Hydrochloride
DrugBank: Rimantadine (DB00478)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimantadine hydrochloride (RH) 100 mg twice a day
Study: 29389150
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy for CHR for psychosis
Study: 29389150
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy for CHR for bipolar disorder
Study: 17530638
Drug: Bosentan (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (125 mg/day)
Study: 20394250
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 2% lidocaine (40 mg) and 0.5 mL atracurium (5 mg)
Study: 20394250
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 2% lidocaine (40 mg) and 0.5 ml 0.9% NaCl (Control)
Study: 17084621
Drug: Sequential chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemo-radiotherapy (Gemcitabine 1250mg/m² days 1, 8; Cisplatin 75mg/m² day 2)
Study: 17084621
Drug: Concurrent chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo-radiotherapy (daily low-dose Cisplatin 6mg/m² with radiotherapy 66Gy)
Study: 17084621
Drug: Concurrent chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo-radiotherapy
Study: 10430432
Drug: Lexipafant 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lexipafant 500 mg/day
Study: 7490991
Drug: Short problem‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short problem‐based training course in pharmacotherapy using a WHO manual on rational prescribing.
Study: 7042363
Drug: Indoprofen 600
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 600 mg/day
Study: 7042362
Drug: Indoprofen 1000
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 1000 mg/day
Study: 7042362
Drug: ASA 3600
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA 3600 mg/day
Study: 1931060
Drug: Midazolam 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.02 mg/kg
Study: 15906066
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone (400 mcg)
Study: 15906066
Drug: Intravitreal vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal vancomycin (0.2 mg)
Study: 11882229
Drug: Ketoprofen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 0.5 mg.kg-1 at induction followed by continuous infusion of 3 mg.kg-1 over 24 h (preketoprofen group)
Study: 11882229
Drug: Ketoprofen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 0.5 mg.kg-1 after surgery followed by continuous infusion of 3 mg.kg-1 over 24 h (postketoprofen group)
Study: 9814468
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy with dose titration starting at 0.8 IU/day subcutaneously (0.4 IU/day if hypertensive or glucose tolerance impaired)
Study: 9814468
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy with dose titration
Study: 8695002
Drug: Amalgambond adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amalgambond adhesive agent
Study: 28167237
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (4000IU/d) vitamin D3
Study: 28167237
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (4000IU/d) vitamin D3 among those with insufficient 25(OH)D (<75nmol/L) at baseline
Study: 25714615
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg alternate days, 12 weeks)
Study: 21685641
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality exposure therapy using head-mounted display (HMD)
Study: 21685641
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality exposure therapy using computer automatic virtual environment (CAVE)
Study: 15228844
Drug: Cyclosporin-A in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin-A in combination with methotrexate